Last reviewed · How we verify
0.5% ropivacaine local anaesthesia
0.5% ropivacaine local anaesthesia, developed by China Medical University, is a marketed product in the local anaesthesia segment. The key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential revenue stability. The primary risk lies in the lack of disclosed primary trial results and competitors, which may impact the drug's market differentiation and long-term competitiveness.
At a glance
| Generic name | 0.5% ropivacaine local anaesthesia |
|---|---|
| Sponsor | China Medical University, China |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial (NA)
- The Effects of Various Concentrations of Ropivacaine on the Onset and Duration of Ankle Blocks (NA)
- CPL-01 in the Management of Postoperative Pain After Bunionectomy (PHASE3)
- Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty (PHASE4)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Popliteal Nerve Block for Acute Achilles Tendon Rupture Repair Surgery (NA)
- Zynrelef Versus Adductor Canal Block (PHASE4)
- PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |